SCHEMBL825498

SCHEMBL825498

O=[N+]([O-])C1=CC(F)([N+](=O)[O-])C(F)C=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1938538 0.78
SCHEMBL9751087 0.67
SCHEMBL5497761 0.67
SCHEMBL2021402 0.67
SCHEMBL1962852 0.67
SCHEMBL11881378 0.66
SCHEMBL8681647 0.65
SCHEMBL4431394 0.65
SCHEMBL3382768 0.64
SCHEMBL5794387 0.64 DNMT3B (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117164576-A Synthesis method of flumioxazin 上海农帆生物科技有限公司 2023-12-05 CN claimed
EP-1549350-A1 PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES Fresenius Kabi Deutschland GmbH (DE) 2005-07-06 EP claimed
WO-2004032971-A1 PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2004-04-22 WO claimed
US-12427172-B2 Ionizing irradiation sterilization of bacterial minicell-based biopharmaceuticals and methods of use VAXIION THERAPEUTICS, LLC (US) 2025-09-30 US disclosed
EP-4284919-A1 METHODS OF MAKING MODIFIED TUMOR INFILTRATING LYMPHOCYTES AND THEIR USE IN ADOPTIVE CELL THERAPY Iovance Biotherapeutics, Inc. (US) 2023-12-06 EP disclosed
CN-117164576-A Synthesis method of flumioxazin 上海农帆生物科技有限公司 2023-12-05 CN disclosed
US-20230321159-A1 IONIZING IRRADIATION STERILIZATION OF BACTERIAL MINICELL-BASED BIOPHARMACEUTICALS AND METHODS OF USE VAXIION THERAPEUTICS, LLC 2023-10-12 US disclosed
EP-4195923-A1 GREEN CLOSED LOOP BIO-WASTE REFINING PROCESS FOR PRODUCING SMART ACTIVE EXTRACTS AND DELIVERY SYSTEMS FOR THEIR APPLICATION Cellacure LLC (US) 2023-06-21 EP disclosed
EP-4147046-A1 HIGH IONIC STRENGTH DISSOCIATION ASSAY FOR HIGH DRUG TOLERANT TESTING F. Hoffmann-La Roche AG (CH) 2023-03-15 EP disclosed
US-11564953-B2 Ionizing irradiation sterilization of bacterial minicell-based biopharmaceuticals and methods of use VAXIION THERAPEUTICS, LLC (US) 2023-01-31 US disclosed
WO-2022165260-A9 METHODS OF MAKING MODIFIED TUMOR INFILTRATING LYMPHOCYTES AND THEIR USE IN ADOPTIVE CELL THERAPY IOVANCE BIOTHERAPEUTICS, INC. (US) 2022-12-22 WO disclosed
EP-0725149-B1 METHOD OF DETECTING NUCLEIC ACID FUSO PHARMACEUTICAL IND (JP) 2002-01-09 EP disclosed
WO-2001096371-A2 ADIPOSE-RELATED GENE DEVELOGEN AG (DE) 2001-12-20 WO disclosed
EP-1159419-A1 PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION Genentech, Inc. (US) 2001-12-05 EP disclosed
WO-2001069245-A2 CROSS-REACTIVE SENSORS TRUSTEES OF TUFTS COLLEGE (US) 2001-09-20 WO disclosed
WO-2000053757-A2 PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION GENENTECH, INC. (US) 2000-09-14 WO disclosed
US-5824474-A Method for detecting nucleic acid FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1998-10-20 US disclosed
EP-0725149-A1 METHOD OF DETECTING NUCLEIC ACID FUSO PHARMACEUTICAL INDUSTRIES LTD. (JP) 1996-08-07 EP disclosed
EP-0359063-A2 Antibody having high affinity to methamphetamine and immunogen for obtaining the same MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1990-03-21 EP disclosed
US-4704355-A ADENOSINE 5*-TRIPHOSPHATE NEW HORIZONS DIAGNOSTICS CORPORATION (US) 1987-11-03 US disclosed